CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 13 enrolled
Drug / intervention
Axitinibdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02129647
NCT02129647Phase 2Completed
CompareCT.gov

Phase II Study of Axitinib in Patients With Neurofibromatosis Type 2 and Progressive Vestibular Schwannomas

NYU Langone Health·interventional·Posted May 2, 2014·Updated Dec 1, 2021

In Brief

A Phase 2 clinical trial evaluating Axitinib for Neurofibromatosis Type 2 and Vestibular Schwannomas. Completed, enrolled 13 participants across 1 site.

Detailed Summary

The purpose of this study is to determine if the study drug, AXITINIB, has any effect on tumors found in patients with Neurofibromatosis Type 2 (NF2).

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsNeurofibromatosis Type 2, Vestibular Schwannomas
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
2014201520162017201820192020202120222023202420252026
First PostedMay 2, 2014
Enrollment StartApr 1, 2014
Primary CompletionFeb 5, 2019
TodayJul 2, 2026
Enrollment to primary: 4.8 yearsPosted 12.2 years ago

Interventions

Axitinibdrug